Vaccine unit continues to bleed for Novartis

Swiss pharma Novartis (NYSE: NVS) continues to see losses with its vaccine unit, a division that has a manufacturing plant in Holly Springs. In an earnings call, Harry Kirsch, chief financial officer, says to expect a negative operating income for vaccines and diagnostics “although the losses are reducing compared to 2012,” he adds. The company reported $411 million in sales for its vaccines and diagnostics net sales and an operating loss of $83 million. Novartis does not separate vaccines… Reported by bizjournals 6 hours ago.